Because human P40 T-cell growth factor, tentatively designated interleukin-9 (IL-9). was isolated through its ability to stimulate a human IL-3-dependent leukemic cell line (M-07E), we tested the ability of IL-9 to support the growth and differentiation of normal hematopoietic progenitor cells from peripheral blood and bone marrow. Although the M-07E cell line was derived from a patient with megakaryoblastic leukemia, IL-9 has not proved to be a growth or maturation factor for megakaryocytes, but instead has proved to be effective in supporting the development of erythroid bursts (BFU-E) in cultures supplemented with erythropoietin. Using highly purified progenitors from peripheral blood, IL-3 showed a BFU-E plating efficiency of 46% compared with 20% for IL-9. Because of
T row or peripheral blood progenitor cells is a complex
process that is supported in culture by several different hematopoietic growth factors. Erythropoietin (Epo), the primary regulator of the levels of circulating erythrocytes in vivo, is absolutely required in culture to support the final stages of erythroid development, including hemoglobinization. The growth and development of earlier erythroid progenitors, known as erythroid burst-forming units (BFU-E), can be supported by several different cytokines, including interleukin-3 (1L-3), granulocyte-macrophage colony-stimulating factor (GM-CSF), and, at least in the mouse system, interleukin-4 (IL-4).'-' However, each of these cytokines interacts with several different hematopoietic cell lineages, and none of them is specific in supporting erythropoiesis.
We recently used a human factor-dependent cell line, M-07E, as a target cell to screen for novel hematopoietic growth factors. The M-07E cells, which are dependent upon either IL-3 or GM-CSF for growth, were originally derived from an infant with megakaryoblastic leukemia.' Surprisingly, functional expression cloning using M-07E cells as targets yielded the human version of murine P40 T-cell growth factor (TCGF)." This cytokine had previously been described as a growth factor for selected murine helper T-cell clones.'' Our results implicated the lymphoid factor P40 TCGF as a potential regulator of hematopoiesis, and we have proposed the designation of IL-9 for this T cell-derived cytokine. We report here that IL-9 in combination with Epo selectively supports the proliferation of erythroid progenitors and has no measureable effects on other hematopoietic cell lineages when tested in clonal culture systems with either peripheral blood, cord blood, or bone marrow target cells. Thus, IL-9 is another cytokine with the potential to serve as a regulator in both the lymphoid and myeloid systems.
MATERIALS AND METHODS

Cytokines and Antibodies
Recombinant human GM-CSF, IL-3, granulocyte colonystimulating factor (G-CSF), IL-4, IL-6, leukemia inhibitory factor (LIF), IL-la, and Epo were all provided by the Genetics Institute the purity of these cell preparations and the low cell density in culture, IL-9 is likely to interact directly with erythroid progenitors. Analysis of mixing experiments and of the morphology of the BFU-E in culture indicated that IL-9 interacts preferentially with a relatively early population of IL-3-responsive BFU-E. In cultures of human bone marrow or cord blood, IL-9 selectively supported erythroid colony formation, while IL-3 and granulocyte/mecrophage colony-stimulating factor additionally yielded granulocyte/ macrophage colonies. Therefore, IL-9 represents a new T cell-derived cytokine with the potential for selectively stimulating erythroid development in the hematopoietic system. 0 1990 by The American Society of Hematology.
(Cambridge, MA). Recombinant human GM-CSF, IL-3, IL-6, G-CSF, and Epo were all purified proteins, having specific activities of 8.7 x IO6, 3 .9 x lo6, 1 x IO6, 2.0 x lo6, and 1.5 x lO'U/mg of protein, respectively. Except for Epo, which was used at a final concentration of 2 U/mL, these proteins were used in culture at a final concentration of 10 ng/mL. IL-4, IL-9, LIF, and IL-la were conditioned media from COS cells that were transfected with the appropriate cDNA. These transfection supernatants had halfmaximal activities of 1.3 x IO4, 6 x IO3, 1 x IO5, and 1.5 x IO', on respective biologic assays. IL-la was used in culture at a concentration of 5 U/mL. The other transfection supernatants were used at a final dilution of 1:lOO. To neutralize endogenous GM-CSF and IL-3 production by contaminating lymphocytes or monocytes, a 1: 100 final dilution of sheep heteroantiserum directed against human GM-CSF or a rabbit heteroantiserum directed against human IL-3 (Genetics Institute), respectively, was added directly to the cultures. In this assay system, this concentration of antibody is capable of completely neutralizing 90 units of human GM-CSF or 40 units of human IL-3.
Cell Preparation
Residual leukocytes were obtained as a byproduct from plateletpberesis of healthy donors using a Fenwal CS-3000 blood separator (provided by the blood bank of the Children's Hospital of Boston). These cells were used in order to isolate peripheral blood progenitors. These progenitors were isolated from cold aggregated monocytes prepared as described initially by any, granulocyte/macrophage colonies were obtained. More highly purified progenitor populations were prepared by positive immunomagnetic selection" for the early hematopoietic cell surface marker CD34 +, using the commercially available HPCA-1 antibody purchased from Becton-Dickinson (Mountain View, CA). This highly purified cell preparation was used in clonal assays at concentrations between 100 and 250 cells/mL and typically yielded a BFU-E plating efficiency of about 50% in the presence of IL-3 and EPO.
Bone marrow was collected by aspiration from normal adult volunteers in preservative-free heparin. Mononuclear cells were isolated by density centrifugation using Ficoll-Paque (Pharmacia, Piscataway, NJ), and adherent cells were removed by overnight adherence to plastic tissue culture dishes in Iscove's modified Dulbecco's medium (IMDM) with 20% fetal calf serum (FCS) at 37°C under 5% CO,.
Umbilical cord blood was obtaind from umbilical cord and placental tissues scheduled for discard under a protocol approved by the Brigham and Women's Hospital Human Investigations Committee (Boston, MA), The cord blood was collected in preservative-free heparin and prepared in a similar fashion to that mentioned for bone marrow.
Bone marrow and cord blood.
Clonal Assay Cultures
Enriched progenitor cells were cultured in 0.5 mL of 0.9% methylcellulose in IMDM with 30% FCS, 0.9% deionized bovine serum albumin (Sigma Fraction V, Sigma, St. Louis, MO), and mol/L 2-mercaptoethanol. Bone marrow and cord blood progenitors were plated at a final concentration of 2.5 x lo4 cells/mL in 48-well dishes. The cultures were incubated at 37O for I O to 14 days. One unit of recombinant erythropoietin (Genetics Institute) was added to each 0.5 mL culture in a dropwise fashion on day 3. In the absence of exogenous growth factors, significant background colony formation was observed most likely due to accessory cell CSF production in cultures of either bone marrow or cord blood progenitors. Red blood cell colonies containing typically greater than 1,000 cells were scored as BFU-E 12 to 14 days after the initiation of triplicate cultures.
RESULTS
For our initial studies with IL-9, we used erythroid progenitors isolated from the leukocytes obtained as a by-product of plateletpheresis. For the purification of the erythroid progenitors, we exploited the ob~ervation'~ that these cells selectively aggregate along with monocytes when peripheral mononuclear cells are incubated at 4OC. The aggregated progenitors were further fractionated and used as target cells in standard erythroid methylcellulose cultures in the presence of Epo. In testing these cells for responsiveness to different cytokines, we found that in addition to IL-3 and GM-CSF, IL-9 proved to be effective in supporting the formation of BFU-E, while G-CSF, IL-la, IL-4, IL-6, and LIF were not ( Table 1) . In this culture system, IL-9 yielded 40% to 50% as many BFU-E as did either IL-3 or GM-CSF. Similar results were obtained in more than 10 separate experiments. The erythroid burst-promoting activity (BPA) of IL-9 was not blocked by addition of neutralizing antiserum against GM-CSF, the most abundant BPA produced by accessory cells in these cultures, or neutralizing antiserum against IL-3, suggesting that IL-9 acts directly on erythroid progenitors. IL-3 alone yielded the highest frequency of BFU-E formation, and this level was not augmented by addition of either 1L-9 or GM-CSF, indicating that the IL-9 and GM-CSF each interact with subsets of IL-3-responsive erythroid progenitors. Careful microscopic analysis revealed significant differences between the colonies supported by IL-3 and IL-9 (Fig 1) . IL-3 yielded at least two distinct types of colonies: a small well-defined colony that was well hemoglobinized by days 10 to 12 of culture, and a larger, more diffuse colony that was not fully hemoglobinized until later, around days 13 to 16. This delayed hemoglobinization most likely indicates that the original progenitor from which the colony was derived was more primitive than those that yield colonies that hemoglobinize earlier. Interestingly, most of the BFU-E supported by IL-9 were of the diffuse, latehemoglobinizing morphology, perhaps indicative of an interaction with a relatively early subpopulation of IL-3-responsive progenitors.
To address the issue of indirect versus direct action of IL-9, we further purified the peripheral blood progenitors through immunomagnetic bead selection for CD34+ cells. When plated in the presence of IL-3 and Epo at concentrations of either 100 or 250 cells/mL, 46% of these cells yielded erythroid bursts (Table I ) . This same cell population revealed BFU-E plating efficiencies of approximately 20% in IL-9 and 42% in GM-CSF. Because of the high purity of these progenitors and the low density of plating, this result provides strong evidence that there is a subpopulation of BFU-E that responds directly to 1L-9.
Because peripheral blood is a relatively poor source of granulocyte/macrophage (GM) progenitors, we compared 1L-9 with 1L-3 and GM-CSF for the ability to support colony formation by progenitors from adult bone marrow and cord blood. Either of these sources, but especially bone marrow, have abundant levels of progenitors from all lineages and are use only. use only.
For personal at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From more appropriate than peripheral blood for testing the lineage specificity of different cytokines. As summarized in Table 2 , IL-9 stimulated the formation of 1.9-to 2.8-fold more erythroid colonies with either target cell population than were observed in cultures supplemented with medium alone. In the same cultures, IL-3 and GM-CSF stimulated erythroid colony formation by 2.5-to 3.7-fold. In neither culture did IL-9 significantly augment colony formation by the progenitors from either the granulocyte or macrophage lineages (CFU-GM, CFU-G, or CFU-M). We did observe a modest stimulation of the formation of multilineage colonies in the IL-9-supported cultures with either target cell populations (two fold or less), but further study will be required to detemine if this effect is direct or indirect. Finally, IL-9 has not revealed any activity in either human or murine bone marrow cultures optimized for megakaryocyte colony formation, providing further evidence for the erythroid specificity of this cytokine with the hematopoietic system (data not shown).
DISCUSSION
The cytokine regulation of the lymphohematopoietic system is becoming increasingly complex. Many cytokines have been described that, at least in vitro, support the growth and development of various stages of lymphoid or myeloid development. Many of these are now recognized to interact with both lymphoid and myeloid cells: IL-4 serves as a multilineage growth factor in the hematopoietic system but also as a TCGF and a B-cell stimulator in the lymphoid s y~t e m ;~.~ IL-5 is a growth and differentiation factor for eosinophils and a growth factor for B cells (at least in the mouse ~y s t e m ) '~; IL-6 acts as a stimulator of very early hematopoietic cells, of megakaryocyte progenitors, and also displays many activities with both T and B cells'6; and IL-7 supports megakaryocyte maturation but also stimulates pre-B cell proliferation and serves as growth factor for T cells." Our results with the human P40 TCGF indicate that this cytokine may also act both in the lymphoid and myeloid systems, providing further justification for its designation as IL-9.
Our analysis with clonal systems of normal cells indicate that within the hematopoietic system, IL-9 is a relatively specific regulator of erythropoiesis. However, we have not tested IL-9 exhaustively in other hematopoietic culture systems nor in all possible combinations with other known cytokines, and, therefore, we cannot exclude the possibility that it might interact with other cell lineages. In cultures with normal human bone marrow cultures, we did observe a small effect on the formation of mixed colonies. This is consistent with the observation that IL-9 preferentially supports the development of a relatively early BFU-E population and suggests that IL-9 responsiveness might appear in an early progenitor cell population before the determination of erythroid commitment. This responsiveness is selectively retained at least through the early stages of erythroid development. Because we originally identified IL-9 through its interaction with the M-07E cell line derived from an infant with megakaryoblastic leukemia, we expected that it might support megakaryocyte development, an expectation that has not been realized (data not shown). However, the M-07E cells also express several surface antigens that are also expressed by erythroid cells, including CD36 and H25
(also found on natural killer cell^).^ Interestingly, the human IL-3dependent erythroid cell line, TF-1," does not respond to IL-9 (data not shown). The relationships of these leukemic cell lines with the normal progenitor counterparts remains to be determined. Thus far, human IL-9 alone has not shown any ability to activate, differentiate, or promote the growth of primary human T cells (Steve Herrmann, personal communication, February 1990). In the mouse system, IL-9 was isolated through its ability to support the proliferation of certain long-term helper T cell clones, but it also has not proved to be a general growth factor for primary T cells." As observed with the leukemic cell lines, it has not been possible to accurately predict the effects of IL-9 with normal cells based on responses with cell lines, and the role of this cytokine in lymphoid development remains to be determined. IL-9, like IL-3, appears to be a relatively specific and abundant product of activated T cells. It most likely is one of the major factors contributing to the erythroid BPA found in peripheral blood lymphocyte conditioned medium. At least in principle, this means that the activated T cells can release 1L-3, GM-CSF, and IL-4 to provide general stimulation for hematopoiesis and IL-9 to stimulate selectively erythropoiesis. It will be interesting to carefully compare the regulation of expression of these cytokines by activated T cells. For example, if they are independently regulated, does this mean that IL-9 might be specifically expressed under special conditions to provide a stimulus for erythropoiesis without affecting other lineages? The answer to this and related questions should provide a better understanding of the mechanisms controlling hematopoiesis.
